当前位置:
首页>产品中心>单抗/多抗>Eldelumab ELISA Kit|Eldelumab ELISA试剂盒(靶标:)
Eldelumab ELISA Kit|Eldelumab ELISA试剂盒(靶标:)
- 货号:RB9TDY524018
- 价格:面议
- 点击:453
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 灵敏度 | 0.156 μg/ml |
|---|
| 检测范围 | 0.31-5 μg/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | P02778 |
|---|
| 背景信息 | Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis. |
|---|
| 别名 | BMS-936557, MDX-1100, 946414-98-8 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: